Related Experiment Videos
[Combined immunologic deficiency]
E J Gerritsen1, H van den Berg, R L Langlois van den Bergh
1Afd. Kindergeneeskunde, Academisch Ziekenhuis, Leiden.
Tijdschrift Voor Kindergeneeskunde
|October 1, 1988
Summary
Severe combined immunodeficiency (SCID) is a heterogeneous disorder. Bone marrow transplantation offers a cure for most SCID patients, even without an HLA-identical donor.
Area of Science:
- Immunology
- Genetics
- Pediatrics
Context:
- Presents clinical and immunological findings of 32 severe combined immunodeficiency (SCID) patients treated over 20 years.
- Discusses the recent WHO classification of combined immunodeficiency diseases.
- Explores the known pathogenesis of various SCID forms.
Purpose:
- To detail the clinical and immunological characteristics of SCID patients.
- To discuss SCID classification and pathogenesis in light of recent findings.
- To review the therapeutic efficacy of bone marrow transplantation (BMT) for SCID.
Summary:
- Severe combined immunodeficiency (SCID) is a group of heterogeneous disorders.
- Bone marrow transplantation (BMT) is the only curative treatment for SCID, with high success rates.
- Advances in carrier detection and antenatal diagnosis are also considered.
Impact:
- Highlights the heterogeneity of SCID, impacting diagnostic and therapeutic strategies.
- Emphasizes the critical role of BMT in SCID treatment, offering hope for recovery.
- Underscores the importance of early diagnosis and intervention for improved patient outcomes.